Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) announced today receipt from the United States Patent and Trademark Office ("USPTO") of a Notice of Allowance for a non-provisional patent application related to our abuse deterrent Aversion(R) Technology platform. A U.S. patent relating to this Notice of Allowance will be granted after the Company pays the required fees. Upon issuance, this patent will be the third U.S. patent covering our Aversion(R) Technology and our opioid analgesic product candidates and broadens our patent coverage to include other abused drug classes such as stimulants and benzodiazepines.
About Acura Pharmaceuticals, Inc.
Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of product candidates intended to introduce limits or impediments to abuse and misuse utilizing our proprietary Aversion(R) and Impede(R) Technologies, and other novel technologies.
No comments:
Post a Comment